Publications

  1. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 2003 Mar 15; 97(6):1442-6.
    View PubMed
  2. Tan W. Malignant mesothelioma. Hospital Medicine. 1998; 34(11):54-6.
  3. Tan W, Chua M. Hemolytic anemia in SLE. The Philippine Journal of Pediatrics. 1989; 38(4):255-8.
  4. Tan W, Schiano TD, Moss D, Herzlich BC. Hepatic artery aneurysm associated with acute gastroenteritis: successful treatment after intraperitoneal rupture. South Med J. 1994 Aug; 87(8):831-2.
    View PubMed
  5. Tan W, Herzlich BC, Funaro R, Koutelos K, Pagala M, Amaladevi B, Grob D. Rhabdomyolysis and myoglobinuric acute renal failure associated with classic heat stroke. South Med J. 1995 Oct; 88(10):1065-8.
    View PubMed
  6. Tan W, Chapnick E, Abter EIM, et al. Paromomycin associated pancreatitis in HIV related cryptosoridiosis. Ann Pharmacother. 1995; 29:22-3.
    View PubMed
  7. Tan WW, Walsh T. Ocular toxicity secondary to paclitaxel in two lung cancer patients. Medical & Pediatric Oncology. 1998 Sep; 31(3):177.
    View PubMed
  8. Mincey BA, Tan W. The management of bone loss in patients with breast or prostate cancer. Support Cancer Therapy. 2004; 1(3):1-7.
    View PubMed
  9. Tan M, Tan W. Osteoporosis in prostate cancer(CME Article). Federal Practitioner. 2004; 21(12):72-9.
  10. Baweja M, Tan W. Bone metastases from Prostate cancer: Known and Novel targets for palliation. Palliative and Supportive Cancer care Journal. 2005; 1(2):47-58.
    View PubMed
  11. Tan M, Tan W. Polypharmacy in the Elders.(CME article) Federal Practitioner. 2005; 22(11):76-88.
  12. Tan W, Tan M. Diagnostic Dilemma: Diagnostic test for bifrontal, intractable headache. Hospital Medicine. 1999; 35(8):212-14.
  13. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005 Jun; 23(3):257-61.
    View PubMed
  14. Lee S, Desai KK, Iczkowski KA, Newcomer RG, Wu KJ, Zhao YG, Tan WW, Roycik MD, Sang QX. Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res. 2006 Sep; 16(9):750-8.
    View PubMed
  15. Tan WW. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control. 2006 Jul; 13(3):194-8.
    View PubMed
  16. Hines SL, Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007 Mar; 82(3):297-300.
    View PubMed
  17. Tan W. [Promising new treatment options for metastatic androgen-independent prostate cancer]. Actas Urol Esp. 2007 Jun; 31(6):680-5.
    View PubMed
  18. Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD, Heckman MG, Crook JE, Clark MM, Rummans TA, Werch CE. Quality of life of men with biochemical recurrence of prostate cancer. J Psychosoc Oncol. 2008; 26(2):17-34.
    View PubMed
  19. Hines SL, Tan W, Larson JM, Thompson KM, Jorn HK, Files JA. A practical approach to guide clinicians in the evaluation of male patients with breast masses. Geriatrics. 2008 Jun; 63(6):19-24.
    View PubMed
  20. Coe SG, Tan WW, Fox TP. Cushing's syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life. J Gen Intern Med. 2008 Jun; 23(6):875-8. Epub 2008 Apr 02.
    View PubMed
  21. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008 Sep; 19(9):1561-5. Epub 2008 Jun 05.
    View PubMed
  22. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7940-6.
    View PubMed
  23. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008; 8:132. Epub 2008 May 11.
    View PubMed
  24. Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2010 Mar; 21(3):493-7. Epub 2009 Jul 22
    View PubMed
  25. Hughes CL, Tan WW, Ferrone M. Sorafenib for the treatment of renal cell carcinoma. J Pharm Technol. 2006; 22(5):281-8.
    View PubMed
  26. Moss JE, Tan WW, Menke DM, Johnson MM. Multiple pulmonary nodules in an asymptomatic man. The Journal of Medicine. 2009; 2(4):205-10.
  27. Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther. 2010; 3:39-51. Epub 2010 Jun 24.
    View PubMed
  28. Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD, Crook JE, Williams CR, Werch CE, Clark MM, Rummans TA. A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. Psychooncology. 2011 Apr; 20(4):435-40. Epub 2010 May 24.
    View PubMed
  29. Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA. Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist. 2010; 15(10):1043-9. Epub 2010 Oct 07.
    View PubMed
  30. Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer. 2005 Sep; 4(2):138-41.
    View PubMed
  31. Tzou K, Tan WW, Buskirk S. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy. Expert Rev Anticancer Ther. 2011 Jan; 11(1):125-36.
    View PubMed
  32. Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther. 2011; 4:97-113. Epub 2011 Jul 11.
    View PubMed
  33. Ames SC, Parker AS, Crook JE, Diehl NN, Tan WW, Williams CR, Ames GE. Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma. J Psychosoc Oncol. 2011; 29(6):593-605.
    View PubMed
  34. Hines S, Tan WW, Moreno A, Roy V, Vallow L, Mclaughlin S, Perez, E. A practical Clinical approach to Adjuvant Therapy in Breast Cancer- An update. US Oncological Review. 2009; 5 (1):49-53.
  35. Andhavaradrapu S, Tan WW. Practical insights and challenges in the rational use of targeted agents in metastatic clear cell renal carcinoma. Cancer and Clinical Oncology. 2012 May; 125(1361):102-104 Epub 2012.
  36. Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer. 2012 Apr; 12(2):81-6.
    View PubMed
  37. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W, North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007 Feb; 69(2):289-94.
    View PubMed
  38. Finn L, Tan W. Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents. ISRN Oncol. 2012; 2012:478607. Epub 2012 Jun 3.
    View PubMed
  39. Ahmad A, Tan W. Atypical Presentation of Prostate Cancer and workup of an adenocarcinoma of Unknown primary. World J Urol. 2012(3(4)):187-190.
  40. Ahmad A, Tan WW. Castrate Resistant Metastatic Prostate Cancer: Options for a Patient in 2012. Open Journal Urology. 2012; 2:210-215 Epub 2012 Oct.
  41. Andhavarapu S, Tan WW. Medical image. papules of unknown aetiology. Disseminated Curvularia. N Z Med J. 2012; 125(1361):102-4. Epub 2012 Sep 07.
    View PubMed
  42. Ahmad A, Wu K, Tan WW. Renal Cell Carcinoma with Skin metastasis: A Case Report and Literature Review. Cancer and Clinical Oncology. 01/2013; 2(1):1-7.
  43. Tan WW, Heckman MG, Vishnu P, Crook JE, Younkin LH, Covil EG, Ferman TJ, Graff-Radford NR, Younkin SG, Smallridge RC, Wehle MJ, Buskirk SJ. Effect of leuprolide on serum amyloid-beta peptide levels and memory in patients with prostate cancer with biochemical recurrence. Urology. 2013 Jan; 81(1):150-4.
    View PubMed
  44. Gardner F, Wu K, Tan WW. Male choriocarcinoma with pulmonary and liver metastases, choriocarcinoma syndrome, and brain metastasis: a case report and review of the literature. Annals of Hematology and Oncology. 2014 Sept 3; 1(1):1-3. Epub 2014 Sep
  45. von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW, Copland JA. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013 May 1; 19(9):2368-80. Epub 2013 Apr 30.
    View PubMed
  46. Tan WW, Dueck AC, Flynn P, Steen P, Anderson D, Rowland K, Northfelt D, Perez EA. N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial. Ann Oncol. 2013 Oct; 24(10):2548-54. Epub 2013 Jun 24.
    View PubMed
  47. Gardner FP, Tan WW. Ataxia in a patient with urothelial carcinoma: Pathologic confirmation, recovery, and improved survival. Clin. adv. hematol. oncol. 2013; 11(7):465-7.
  48. Valery JR , Tan W , Cortese C . Renal leiomyosarcoma: a diagnostic challenge. Case Rep Oncol Med 2013; 2013:459282 Epub 2013 Oct 29
    View PubMed
  49. Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot H, Tan W, Miles KM, Erlichman C, Vaishampayan U. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):477-83. Epub 2013 Jul 26.
    View PubMed
  50. Ames SC, Pokorny SB, Schroeder DR, Tan W, Werch CE. Integrated smoking cessation and binge drinking intervention for young adults: a pilot efficacy trial. Addict Behav. 2014 May; 39(5):848-53. Epub 2014 Feb 12.
    View PubMed
  51. Huang X, Yuan T, Liang M, Du M, Xia S, Dittmar R, Wang D, See W, Costello BA, Quevedo F, Tan W, Nandy D, Bevan GH, Longenbach S, Sun Z, Lu Y, Wang T, Thibodeau SN, Boardman L, Kohli M, Wang L. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 2015 Jan; 67 (1):33-41 Epub 2014 Aug 14
    View PubMed
  52. Gupta E, Guthrie T, Tan W. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC Urol. 2014; 14:55. Epub 2014 Jul 25.
    View PubMed
  53. Tan W, Boorjian S, Advani P, Farmer S, Lohse C, Cheville J, Kwon E, Leibovich B. The Estrogen Pathway: Estrogen Receptor-alpha, Progesterone Receptor, and Estrogen Receptor-beta Expression in Radical Cystectomy Urothelial Cell Carcinoma Specimens. Clin Genitourin Cancer. 2015 Oct; 13(5):476-84. Epub 2015 Apr 15
    View PubMed
  54. Copland JA, Marcus J, Wu K, Cernigliaro JG, Tan WW. A patient with metastatic clear cell renal carcinoma with long term survival spanning the era of pre-targeted to molecular targeted treatment. Annals of Hematology & Oncology 4 [Peer-reviewed article]. 2014 Nov; 1(2).
  55. Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Tan Winston MD FACP *. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology. 2014 Jan; 83(1):159-65. Epub 2013 Nov 12
    View PubMed
  56. et al , Wang Z , Zhu B , Zhang M , Parikh H , Jia J , Chung CC , Sampson JN , Hoskins JW , Hutchinson A , Burdette L , Ibrahim A , Hautman C , Raj PS , Abnet CC , Adjei AA , Ahlbom A , Albanes D , Allen NE , Ambrosone CB , Aldrich M , Amiano P , Amos C , Andersson U , Andriole G Jr, Andrulis IL , Arici C , Arslan AA , Austin MA , Baris D , Barkauskas DA , Bassig BA , Beane Freeman LE , Berg CD , Berndt SI , Bertazzi PA , Biritwum RB , Black A , Blot W , Boeing H , Boffetta P , Bolton K , Boutron-Ruault MC , Bracci PM , Brennan P , Brinton LA , Brotzman M , Bueno-de-Mesquita HB , Buring JE , Butler MA , Cai Q , Cancel-Tassin G , Canzian F , Cao G , Caporaso NE , Carrato A , Carreon T , Carta A , Chang GC , Chang IS , Chang-Claude J , Che X , Chen CJ , Chen KY , Chen YM , Chokkalingam AP , Chu LW , Clavel-Chapelon F , Colditz GA , Colt JS , Conti D , Cook MB , Cortessis VK , Crawford ED , Cussenot O , Davis FG , De Vivo I , Deng X , Ding T , Dinney CP , Di Stefano AL , Diver WR , Duell EJ , Elena JW , Fan JH , Feigelson HS , Feychting M , Figueroa JD , Flanagan AM , Fraumeni JF Jr, Freedman ND , Fuchs CS , Gago-Dominguez M , Gallinger S , Gao YT , Gapstur SM , Garcia-Closas M , Garcia-Closas R , Gastier-Foster JM , Gaziano JM , Gerhard DS , Giffen CA , Giles GG , Gillanders EM , Giovannucci EL , Goggins M , Gokgoz N , Goldstein AM , Gonzalez C , Gorlick R , Greene MH , Gross M , Grossman HB , Grubb R 3rd, Gu J , Guan P , Haiman CA , Hallmans G , Hankinson SE , Harris CC , Hartge P , Hattinger C , Hayes RB , He Q , Helman L , Henderson BE , Henriksson R , Hoffman-Bolton J , Hohensee C , Holly EA , Hong YC , Hoover RN , Hosgood HD 3rd, Hsiao CF , Hsing AW , Hsiung CA , Hu N , Hu W , Hu Z , Huang MS , Hunter DJ , Inskip PD , Ito H , Jacobs EJ , Jacobs KB , Jenab M , Ji BT , Johansen C , Johansson M , Johnson A , Kaaks R , Kamat AM , Kamineni A , Karagas M , Khanna C , Khaw KT , Kim C , Kim IS , Kim JH , Kim YH , Kim YH , Kim YH , Kang CH , Jung YJ , Kitahara CM , Klein AP , Klein R , Kogevinas M , Koh WP , Kohno T , Kolonel LN , Kooperberg C , Kratz CP , Krogh V , Kunitoh H , Kurtz RC , Kurucu N , Lan Q , Lathrop M , Lau CC , Lecanda F , Lee KM , Lee MP , Le Marchand L , Lerner SP , Li D , Liao LM , Lim WY , Lin D , Lin J , Lindstrom S , Linet MS , Lissowska J , Liu J , Ljungberg B , Lloreta J , Lu D , Ma J , Malats N , Mannisto S , Marina N , Mastrangelo G , Matsuo K , McGlynn KA , McKean-Cowdin R , McNeill LH , McWilliams RR , Melin BS , Meltzer PS , Mensah JE , Miao X , Michaud DS , Mondul AM , Moore LE , Muir K , Niwa S , Olson SH , Orr N , Panico S , Park JY , Patel AV , Patino-Garcia A , Pavanello S , Peeters PH , Peplonska B , Peters U , Petersen GM , Picci P , Pike MC , Porru S , Prescott J , Pu X , Purdue MP , Qiao YL , Rajaraman P , Riboli E , Risch HA , Ryu JS , Schwartz AG , Schwartz KL , Shen H , Su WC , Tan W , Taylor PR , Wang C , Wu C , Yin Z , Yuan JM , Zhou B .drulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet 2014 Dec 15; 23 (24):6616-33 Epub 2014 July 15
    View PubMed
  57. Tan WW , Allred JB , Moreno-Aspitia A , Northfelt DW , Ingle JN , Goetz MP , Perez EA . Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. Clin Breast Cancer 2016 Apr; 16 (2):82-6 Epub 2015 Nov 17
    View PubMed
  58. Chen RC , Rumble RB , Loblaw DA , Finelli A , Ehdaie B , Cooperberg MR , Morgan SC , Tyldesley S , Haluschak JJ , Tan W , Justman S , Jain S . Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol 2016 Feb 16 [Epub ahead of print]
    View PubMed
  59. Hart SN , Ellingson MS , Schahl K , Vedell PT , Carlson RE , Sinnwell JP , Barman P , Sicotte H , Eckel-Passow JE , Wang L , Kalari KR , Qin R , Kruisselbrink TM , Jimenez RE , Bryce AH , Tan W , Weinshilboum R , Wang L , Kohli M . Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer. BMJ Open 2016; 6 (4):e010332 Epub 2016 Apr 15
    View PubMed